I was wondering if other member of the board can chime in on this. It seems like OGXI has put much of its resources on Apatorsen, as evidents by all the trials ranging for NSCL, bladder, pancreatic, and prostate cancer. There are clinical trials on Prostate (first and 2nd line) and NSCL cancer for Custirsen. IF you do a pubmed seardch on Apatorsen, there are no published reports of its efficacy. I was wondering OGXI's management's stategy to focus on Apatorsen given the lack of data while Custirsen has published data for different chemo combos for prostate as well as NSCL cancer.. Do they had internal data not publsihed to the public. Are they simply trying to diversify or is it because Apatorsen is an unpartnered product.
Its also worth giving the Company website a look as they have a summary of the results from the OGX-427 trials completed to date.
PubMed my have more information on the target as well - heat shock protein 27, or hsp27.
Part of what I find exciting here is that this phase 2 program for apatorsen is predominantly investigator funded, which obviously makes it much less expensive for the company to fund, but provides a modicum of validation because of the investigators involved. If you go to clinicaltrials.gov you can get a see the lead investigators for these trials, who are really key opinion leaders in their fields. I don't think investigators of this stature would be waisting precious grant dollars on large phase 2 apatorsen trials if they didn't have promise.